Angiotensin Converting Enzyme Inhibition Early after Heart Transplantation

BACKGROUND: Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality after heart transplantation (HT). Angiotensin converting enzyme inhibitors (ACEIs) may retard the development of CAV, but have not been well studied after HT. OBJECTIVES: We tested the safety and efficacy of the AC...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Am Coll Cardiol
Glavni autori: Fearon, William F., Okada, Kozo, Kobashigawa, Jon A., Kobayashi, Yuhei, Luikart, Helen, Sana, Sean, Daun, Tiffany, Chmura, Steven A., Sinha, Seema, Cohen, Garett, Honda, Yasuhiro, Pham, Michael, Lewis, David B., Bernstein, Daniel, Yeung, Alan C., Valantine, Hannah A., Khush, Kiran
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546225/
https://ncbi.nlm.nih.gov/pubmed/28595700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacc.2017.03.598
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items